Advertisement

Collaboration › Details
Editas Medicine–Chardan: investor conference, 201910 supply service Editas participates in Chardan Genetic Medicines Conference in New York
![]() |
Period | 2019-10-07 � 2019-10-08 |
![]() |
Region | New York, NY |
Country | United States (USA) | |
![]() |
Partner, 1st | Editas Medicine Inc. (Nasdaq: EDIT) |
Partner, 2nd | Chardan Capital Markets LLC | |
![]() |
Product | Chardan Genetic Medicines Conference 2019 New York |
Product 2 | CRISPR gene editing technology | |
![]() |
Source | Editas Medicine, Inc.. (8/6/19). "Press Release: Editas Medicine Announces Second Quarter 2019 Results and Update". Cambridge, MA. |
Record changed: 2019-09-02 |
Advertisement

More documents for Editas Medicine Inc. (Nasdaq: EDIT)
- [1] Editas Medicine, Inc.. (7/7/20). "Press Release: Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing". Cambridge, MA & Waltham, MA....
- [2] Editas Medicine, Inc.. (6/26/20). "Press Release: Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares". Cambridge, MA....
- [3] Editas Medicine, Inc.. (6/23/20). "Press Release: Editas Medicine Announces Offering of Common Stock". Cambridge, MA....
- [4] Editas Medicine, Inc.. (6/23/20). "Press Release: Editas Medicine Announces Pricing of Offering of Common Stock". Cambridge, MA....
- [5] Editas Medicine, Inc.. (6/12/20). "Press Release: Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease". Cambridge, MA....
- [6] Editas Medicine, Inc.. (5/15/20). "Press Release: Editas Medicine Presents Pre-Clinical Data Supporting the Use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies". Cambridge, MA....
- [7] Editas Medicine, Inc.. (5/7/20). "Press Release: Editas Medicine Announces First Quarter 2020 Results and Update". Cambridge, MA....
- [8] Editas Medicine, Inc.. (4/29/20). "Press Release: Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers". Cambridge, MA....
- [9] Editas Medicine, Inc.. (2/26/20). "Press Release: Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update". Cambridge, MA....
- [10] Editas Medicine, Inc.. (1/9/20). "Press Release: Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth. Michelle Robertson Joins as Chief Financial Officer". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top